Royce & Associates LP Acquires 14,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Royce & Associates LP lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 64.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,000 shares of the company's stock after acquiring an additional 14,500 shares during the period. Royce & Associates LP owned approximately 0.08% of Axsome Therapeutics worth $3,131,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $52,000. R Squared Ltd bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $64,000. KBC Group NV lifted its holdings in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the period. Moors & Cabot Inc. bought a new stake in shares of Axsome Therapeutics during the 3rd quarter worth approximately $200,000. Finally, Flower City Capital bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $254,000. Institutional investors own 81.49% of the company's stock.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Remove Ads

Axsome Therapeutics Trading Up 0.4 %

NASDAQ AXSM traded up $0.52 on Friday, hitting $126.79. The company's stock had a trading volume of 789,781 shares, compared to its average volume of 640,623. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The company's 50-day moving average is $116.56 and its 200 day moving average is $100.17. The firm has a market cap of $6.18 billion, a PE ratio of -21.17 and a beta of 0.99.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. As a group, analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AXSM has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $153.00 price target on shares of Axsome Therapeutics in a report on Monday, March 3rd. Leerink Partners increased their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, February 10th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective for the company. Morgan Stanley increased their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $167.36.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.